Studies from Novo Nordisk will give the strongest indication yet of whether blockbuster GLP-1 drugs, a class being used by millions for diabetes and weight loss, can slow progress of Alzheimer's disease. #News #Reuters #Newsfeed #novonordisk #alzheimers Read the story here: https://reut.rs/48oHZou 👉 Subscribe: http://smarturl.it/reuterssubscribe Keep up with the latest news from around the world: https://www.reuters.com/ Follow Reuters on Facebook: https://www.facebook.com/Reuters Follow

Tag-uri: Facebook